Pediatric Inflammatory Bowel Disease

Fuller, Megan K.

doi:10.1016/j.suc.2019.08.008

Cited by 36 publications

(38 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pediatric patients with inflammatory bowel disease often present with more extensive and clinically severe disease than adult patients with inflammatory bowel disease, which is known to hinder pediatric growth and development. 5 , 6 Adequate drug exposure is vital to achieve and maintain clinical remission. 6 Variable drug clearance among patients with inflammatory bowel disease is often associated with factors such as body size/weight, disease severity, serum albumin levels, development of antidrug antibodies, and other factors.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial

Zhang¹,

Scalori

Fuh³

et al. 2021

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Background Etrolizumab, a humanized anti-β7 antibody, has not been studied in children. Here, we evaluate the pharmacokinetics, pharmacodynamics, and safety of etrolizumab in children with inflammatory bowel disease. Methods Patients age 4 to 17 years with moderately to severely active ulcerative colitis or Crohn’s disease were randomized 1:1 to receive 1.5mg/kg of etrolizumab subcutaneously every 4 weeks (q4w) or 3.0mg/kg every 8 weeks (q8w) for 16 weeks in this open-label phase 1 trial. Pharmacokinetics, pharmacodynamics, safety, and efficacy were assessed. Results Of the 24 patients treated, 21 completed the study. In the groups of 1.5mg/kg q4w and 3.0mg/kg q8w, respectively, mean (SD) maximum concentration (Cmax) was 9.8 (4.86) µg/mL and 18.1 (6.25) µg/mL; and mean (SD) area under the curve within a dosing interval (AUCtau) was 167 (86.9) and 521 (306) μg·day/mL after the last dose. The Cmax increased dose proportionally. The AUC over an 8-week period was slightly higher in the 3.0mg/kg q8w dose group. Median half-life was similar for both dosing regimens. Median numbers of free β7high gut-homing T and B cell subsets declined below 10% of baseline, confirming β7 target engagement and complete/near-complete receptor occupancy. Adverse events were consistent with the safety profile in adults. Approximately 60% of patients achieved a clinical response. Conclusions Etrolizumab showed a dose-proportional increase in Cmax and a slightly greater than dose-proportional increase in AUCtau. Both regimens achieved complete/near-complete β7 receptor occupancy, with a similar relationship to concentration as adults. Etrolizumab was well tolerated and demonstrated clinical activity in children.

show abstract

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial

Zhang¹,

Scalori

Fuh³

et al. 2021

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…Quanto à presença de história familiar para DII, Figueirêdo et al (2004), Karolewska-Bochenek et al (2009 e Lima et al (2013) observaram, ainda que em variado grau de parentesco, positividade em seus pacientes; o que reforça o pressuposto de que a história familiar se mantém como um forte fator de risco para a DII (Fuller, 2019).…”

Section: Resultsunclassified

Perfil da Doença Inflamatória Intestinal em serviço de referência em gastropediatria no nordeste brasileiro

Araujo

Luz

Mouzinho

2022

RSD

View full text Add to dashboard Cite

Objetivo: Identificar o perfil de pacientes com Doença Inflamatória Intestinal acompanhados em serviço de Gastropediatria do Nordeste Brasileiro. Metodologia: Série de casos através da busca ativa de prontuários de abril a novembro de 2020, tendo como critério de inclusão o acompanhamento regular no serviço de Gastropediatria e de não inclusão prontuários incompletos (sem critérios clínicos, laboratoriais, endoscópicos e/ou histopatológicos de Doença Inflamatória Intestinal), com uma amostra final de 22 participantes. Resultados: A maioria era do sexo masculino (63,6%), portadora de Retocolite Ulcerativa (59,1%) e procedente da capital (63,6%). Os sintomas principais foram: diarreia com sangue (63,6%), dor abdominal (27,3%) e diarreia sem sangue (9%). Calprotectina Fecal estava elevada (88,9%) e anemia presente (77,3%). A maioria encontrava-se eutrófica (59,1%). Foram utilizados corticoide (72,7%) e Mesalazina (27,3%) na fase de remissão, enquanto Azatioprina (18,2%) e imunobiológicos (36,6%) no seguimento. Conclusão: Ainda são esperados mais trabalhos sobre essa temática, assim como são necessários profissionais capacitados e serviços de saúde efetivos para acolher precocemente e referenciar a longo prazo esses pacientes para melhorar a sua qualidade de vida e impactar positivamente na evolução da doença.

show abstract

“…Early genetic to intestinal microecology research, as well as mucosal immune-related studies, have been key in understanding the underlying mechanism of inflammatory bowel disease, and biologics targeting pathogenesis have achieved a precise effect for disease control or remission ( 10 – 12 ). However, the long-term outcome of patients with inflammatory bowel disease has not been significantly improved ( 13 , 14 ), and it remains difficult to identify a solution based on the pathogenesis ( 15 ). Therefore, it is a reasonable to focus on the final pathological state, which is fibrosis, and develop strategies that can potentially alter the natural disease course and long-term outcome of patients.…”

Section: Introductionmentioning

confidence: 99%

Atractylenolide III inhibits epithelial‑mesenchymal transition in small intestine epithelial cells by activating the AMPK signaling pathway

et al. 2022

View full text Add to dashboard Cite

Pediatric Inflammatory Bowel Disease

Cited by 36 publications

References 27 publications

Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial

Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial

Perfil da Doença Inflamatória Intestinal em serviço de referência em gastropediatria no nordeste brasileiro

Atractylenolide III inhibits epithelial‑mesenchymal transition in small intestine epithelial cells by activating the AMPK signaling pathway

Contact Info

Product

Resources

About